Clinical Trials

Biliary Tract Malignancies

NCT04393506 2023-11-22

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

21 enrolled

Head & Neck

Mouth Neoplasms

NCT03396211 2023-04-07

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

30 enrolled

Neoplasm Metastasis, Neoplasms

NCT04322552 2022-11-07

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

18 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04457180 2022-10-26

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

18 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04428086 2022-07-26

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

19 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT02711969 2022-07-22

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

6 enrolled

Stomach Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

98 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05001412 2021-08-12

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

36 enrolled

Extensive Stage Small Cell Lung Cancer

NCT02645864 2021-03-18

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

12 enrolled

Esophageal Squamous Cell Carcinoma

NCT04665362 2021-01-22

IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

10 enrolled

Carcinoma, Hepatocellular

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

22 enrolled

NSCLC

NCT03407976 2020-07-15

APPEASE

Phase 1 Terminated

5 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Transitional Cell

NCT03645200 2019-04-25

Treatment of Carrying TP53 Harmful Mutations

60 enrolled

Advanced Cancer

NCT03245307 2018-02-07

A Study To Test The Effect Of Apatinib On P450 Enzymes

Cytochrome P450 Interaction

NCT03243643 2017-09-08

HS:Hansoh;

80 enrolled

Advanced Cancer

NCT03276156 2017-09-08

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

12 enrolled

Stomach Neoplasms

NCT03026881 2017-03-07

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

24 enrolled

Recurrence, Stomach Neoplasms

NCT02836171 2017-02-27

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Neoplasms

NCT02836821 2017-02-27

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Neoplasms

NCT03050411 2017-02-10

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02691871 2016-02-25

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Adenocarcinoma of Lung

NCT00633490 2008-07-22

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

18 enrolled